Interesting qute from hedge fund manager behind Baupost - key point "legitimate concerns carried to excess" as in the case of MYR.
On the other hand, Baupost is finding value among some firms attacked by the likes of Amazon. “Increasing technological disruption is already pushing some securities well below our assessment of underlying value,” writes
Mr. Klarman, “as legitimate concerns are, in some cases, carried to excess.”
As an example, he cites department stores: “Even for Macy’s, the correct price today is not zero,” says the letter.
“Macy’s owns valuable real-estate assets, and there may be ways to navigate through the current environment while salvaging some value for shareholders.”
- Forums
- ASX - By Stock
- MYR
- A Contrarian Buy
A Contrarian Buy, page-79
-
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
Add MYR (ASX) to my watchlist
(20min delay)
|
|||||
Last
80.0¢ |
Change
0.010(1.27%) |
Mkt cap ! $665.4M |
Open | High | Low | Value | Volume |
79.0¢ | 81.0¢ | 79.0¢ | $2.299M | 2.872M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10060 | 79.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
80.0¢ | 37136 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10060 | 0.795 |
1 | 12658 | 0.790 |
2 | 31468 | 0.785 |
3 | 78700 | 0.780 |
1 | 17 | 0.770 |
Price($) | Vol. | No. |
---|---|---|
0.800 | 37136 | 2 |
0.805 | 75000 | 1 |
0.810 | 94737 | 3 |
0.815 | 49078 | 2 |
0.820 | 52283 | 10 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
MYR (ASX) Chart |